Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn), after receiving regulatory approvals and fulfilling customary ...

The transaction, finalized following regulatory clearance, includes two FDA-approved rare tumor therapies: Ogsiveo for ...

German pharmaceutical giant Merck has completed a €3 billion ($3. 5 billion) takeover of US biopharmaceutical company ...

Merck KGaA, Darmstadt, Germany has closed the acquisition of SpringWorks Therapeutics Inc. for an enterprise value of $3.4 billion.

Argenx wants to get in on the macrocyclic peptide action, penning a deal worth $1.5 billion in biobucks with Californian ...

Iya Khalil, PhD, discusses Merck & Co.’s approach to artificial intelligence (AI), and success in applying the technology, ...

Leading companies spent $1.4 billion upfront on licensing deals and embarked on vast R&D programs. Clinical setbacks mean ...

SpringWorks Therapeutics Inc. (NASDAQ: SWTX) is one of the best biotech stocks to invest in now. On June 20, SpringWorks ...

During a live event, Hari Deshpande, MD, and participants discussed the DeFi trial and the management of nirogacestat in ...

SpringWorks Therapeutics Inc . (NASDAQ: SWTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases and cancer, has been at the center of significant ...

SpringWorks Therapeutics has established itself as a promising player in the U.S. Small & Mid Cap Biotechnology sector. The company’s primary focus has been on developing innovative therapies ...